

OPRTS

09/125747  
300Rec PCT/PTO 25 AUG 1998  
PCT/FR97/00334

WO 97/30716

**ANTI-HELICOBACTER VACCINE COMPLEX**

The present invention relates to a therapeutic and preventive anti-bacterial vaccine complex which possesses a vaccinating power linked to the presence of specific antigens against Helicobacter pylori (previously called Campylobacter pylori), Helicobacter hepaticus, Helicobacter coronari, and nonspecific antigens providing immunomodulation.

[MARSHALL B.J., WARREN Jr., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration *Lancet* 1984: i:1311-4)].

[MÉGRAUD F., *Helicobacter pylori*, the most important bacterium among the mucus bacteria, *La lettre de l'infectiologue* 1993; 8 (suppl. 4): 151-9].

It is well known, in bacteriology, that the surface antigens of the walls, membranes or capsules (combined or free in soluble form in the culture medium) are of a glycoprotein, polypeptide or polysaccharide nature.

Vaccines combining associative factors, such as membrane proteoglycan or polysaccharide substances, extracted from pathogenic microbes, with ribonucleic acid of ribosomal origin (RNA) can be used in the production of acellular vaccines (cf. *Inf. and Immunity*, 1, 574-82, 1970 and PCT WO 94/22462).

These vaccines use specific antigens corresponding to specifically determined microbial diseases.

However, the antigenicity is essentially linked to the level of RNA (of the ribosomes in particular) in microbial cells, inter alia. Immunocompetent cells (ICC)

0015747-00334

directly use these RNAs as active carriers.

b2

To produce the complex of the invention, with the *Helicobacter* bacterial serotype antigen, we coupled preferably by means of covalent bonds, RNA, preferably of ribosomal origin, with an amino acid sequence of glycoprotein nature, preferably present in type III collagen. In humans, collagen represents approximately a third of the proteins in the body. The type III was chosen for its amino acid sequence and its presence in the dermis, the vascular wall and the digestive epithelial mucous membranes.

In our complex, we have used, as stabilizer, cell membrane fractions derived from the same microbes as those which served for the production of the ribosomal RNA. These membrane fractions contain all of the peptidoglycan substances and are known, in addition, as immunity adjuvants.

It is, in addition to *Helicobacter pylori*, *hepaticus* and *coronari*, useful to have - glucopoly-saccharide or proteoglycan - membrane fractions derived from various microbial organisms which have served to provide the RNA by extraction of their ribosomes, which microbes are known for their immunogenesis (recruitment of macrophages, activation of T lymphocytes, potentiation of the synthesis of immunoglobulins, secretory IgA's in particular (11 S), increase in phagocytosis and stimulation of dependent T cells and the like).

This was thus thought of because, in the precise case of the pathogenesis induced by *Helicobacter pylori*,

C hepaticus or helmannii, coronari, the body must produce, in addition to the specific humoral immune response, a cellular response in order to make up for the inefficacy of the antibodies in protecting the individual. O

5 It is known that cell-mediated response does not give rise to the production of antibodies, but only to the generation of sensitized lymphoid cells specific for the antigen involved.

The T lymphocytes act by themselves and/or  
10 through the cytokines, and either an inflammatory type response or a cytotoxic response is observed.

The pathogenic power of *Helicobacter* lies in its ability to colonize the gastric mucous membrane, to survive in the gastric juice and to multiply therein in  
15 spite of the host's immune response, and to generate lesions which are sometimes irreversible (adenocarcinoma, gastric lymphoma or MALT "mucous associated lymphoid tissue" lymphomas),

C [PARSONNET J: Helicobacter pylori and gastric  
20 cancer. Gastroenterol Clin North Am 1993, 22:89-104.

WORTHERSPOON A.C., DOGLIONI C., DISS T. C.  
et al.: Regression of primary low-grade B-cell gastric lymphoma of mucosa associated lymphoid tissue type after  
C eradication of Helicobacter pylori. Lancet 1993; 342:575-  
25 7.

MOHANDAS, *Helicobacter pylori* and lymphoma, N Eng J Med 1994: 331:746-7].

when it is insufficient during injection: resistance to phagocytosis, induction of apoptosis and the like.

[PETERSON P.K., VERHOEF J., SCHMELING D. & QUIE P.G.: Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leucocytes and monocytes, J. Infec. Dis. 136:502-509, 1977.

- 5 KIEHLBAUCH J.A., ALBACH R.A., BAUM I.K., CHANG  
C K.P. Phagocytosis of Campylobacter jejuni and its intracellular survival in mononuclear phagocytes, Infect Immun 1985; 48:446-51].

B<sup>6</sup> Constituents of the vaccine complex which is the subject  
10 of the invention

The complex of the invention comprises dual molecules constituted by the coupling of a functional amino acid arm, ensuring binding to a target, with a genetic RNA arm corresponding to the coded description of  
15 the composition of the functional arm.

A - The RNAs of ribosomal origin which can be used may be extracted from the strains chosen from the following group, this list not being limitative:

- C - Helicobacter pylori (or Campylobacter),  
C 20 hepaticus, coronari ...  
C - Klebsiella pneumoniae  
C - Streptococcus (pneumoniae and pyogenes)  
C - Staphylococcus aureus  
C - Serratia marcescens  
C 25 - Escherichia coli  
C - Salmonella typhimurium  
C - Corynebacterium (granulosum, parvum, acnes)  
C - Mycobacterium (tuberculosis, smegmatis, chelonae)  
C - Haemophilus influenzae

- C - Pneumococcus type II
- C - Rothia dentocariosus
- C - Bacterium coli
- C - Shigella dysenteriae
- 5 C - Enterococcus
- C - Nocardia (asteroides, brasiliensis, rhodocrans,  
C opaca, rubra)
- C - Calmette-Guerin bacillus,  
or from a mixture thereof.

10 The average molecular weights of these RNAs are between 5104 and 108 Dalton.

Many industrial processes exist for the preparation of RNA. We will cite as an example the process for extracting RNA described in Infect. and Immunity, 1. 574-  
15 82. 1970; the bacteria are ground and then subjected to fractional precipitation, the ribosomal proteins are solubilized, the RNA precipitated is treated with Pronase and, finally, purified by ion-exchange chromatography.

If the RNA is obtained by enzymatic route, the  
20 final purification may be carried out by molecular sieve chromatography. See in particular on this subject:

- C. EHRESMAN (1972) - Biochimie, 54, 901
- H. KAGAWA (1972) - J. Biochem., (1972), 827
- M. SANTER (1973) - J. Bact., 116, 1304
- 25 - NOMURA (1974) - Ribosomes - Ed. Cold Spring Harbor Laboratory.

B - The membrane fractions of bacterial cells which can be used may be extracted from the following strains, the lists given not being limitative:

00454-0000-2425100

1 - for capsular polysaccharides

- C a. Helicobacter pylori and hepaticus  
C b. Klebsiella pneumoniae  
C c. Streptococcus pneumoniae  
5 C d. Hemophilus influenzae  
C e. Escherichia coli  
C a. Helicobacter pylori, hepaticus and coronari  
[HILLS B.A., Gastric mucosal barrier: evidence  
C for Helicobacter pylori ingesting gastric surfactant and  
10 deriving protection from it. Gut. 1993 May: 34(5): 588-  
93.

GENTA R.M., ROBASON GO, GRAHAM D.Y., Simultaneous  
C visualization of Helicobacter pylori and gastric  
morphology; a new strain. Human Pathology; 1994 Mar: 25  
15 (3); 221-6.

MAJEWSKI S.I., and C.S. GOODWIN, 1988,  
Restriction endonuclease analysis of the genome of  
C Campylobacter pylori with a rapid extraction method:  
evidence for considerable genomic variation. J. Infect.  
20 Dis. 157; 465-471.

GEIS G., LEYING H., SUERBAUM S., MAI U. &  
OPFERKUCH W.: Ultrastructure and chemical analysis of  
C Campylobacter pylori flagella. J. Clin. Microbiol, 27;  
436-441, 1989].  
C 25 b. Klebsiella pneumoniae

[C. ERBING, L. KENNE, B. LINBERG, J. LONNGREN  
(1976) - Structural studies of the capsular poly-  
C saccharide of Klebsiella pneumoniae type I (Carbohydr.  
Res., 50 (1976) 115-20).

W. NIMMICH (1968) Zur Isolierung und qualitativen Bausteinanalyse der K. Antigen von Klebsiellen [Isolation of the Klebsiella K antigen and qualitative analysis of its structural components] (Med. Mikrobio and Immunol., 5 154, 117, 131).

C. RICHARD (1973) - Etude antigenique et biochimique de 500 souches de Klebsiella [Antigenic and biochemical study of 500 Klebsiella strains] (Ann. Biol. Clin., 1973)].

C 10 c. Streptococcus pneumoniae:

[F. KAUFFMANN and E. LUND (1954) (Int. Bull. Bact. Nomencl. 4, 125-28).

FELTON and OTTINGER (J. of Bacteriology, 1942, 43, 94, 105)

15 M. COLIN, M.D. MAC LEOD et al., Prevention of pneumococcal pneumoniae by immunization with specific capsular polysaccharides (J. Exp. Med., 1945, 82, 445-65).

A.R. DOCHEZ and O.T. AVERY - The elaboration of 20 specific soluble substance by Pneumococcus during growth (1971) (J. Exp. Med. 26, 477-93).

WEST PHAL and LUDERITZ (1952) (Z. Naturf. 7B, 148).

C.P.J. GLAUDEMANS and H.P. TREFFERS - An improved 25 preparation of the capsular polysaccharide from C Diplococcus pneumoniae (Carbohydr. Res. 1967, 4, 181-84)].

C d. Hemophilus influenzae (capsular polysaccharide polyribosephosphate type)

[P. ANDERSON et al. (1972) - Immunization of humans with polyribosephosphate, the capsular antigen of C Hemophilus influenzae type B (J. of Clin. Invest., vol. 51, 1972, 39-44).

5 P. ANDERSON et al. (1977) - Isolation of the capsular polysaccharide from supernatant of C Hemophilus influenzae type B (Infect. and Immun., 1977, 15 (2), 472-77)].

C e. Escherichia coli (capsular polysaccharides)

10 [LUDERITZ et al. (1977) - Somatic and capsular antigens of gram-negative bacteria (Compr. Biochem. 26 A, 105-228).

BOYER H.W. and D. ROULLAND-DISSOIX, (1969) - A complementation analysis of the restriction and  
15 modification in *Escherichia coli*, J. Mol. Biol. (41:459-472).

CASADABAN, M. and S. N. COHEN (1980) - Analysis of gene control signals by DNA fusion and cloning in *E. coli*, J. Mol. Biol. (138; 179-207).

20 LUGTENBERG B., J. Meijers, R. Peters, P van der Hock and L. van Alphen (1975) - Electrophoretic resolution of the "major outer membrane protein" of C Escherichia coli K12 into four bands. (FEBS Lett. 58; 254-258)].

25 2 - For the membrane lipopolysaccharides (LPS) -

C Corynebacterium (avidum, bovis, diphteriae, enzymicum, equi, fascians, flaccum, faciens, flavidum, fustiforme, granulosum, helvolum, hypertrophicans, insidiosum, liquefaciens, parvum, paurometabolum, pyogenes,

sub  
C1



~~C tumescens, xerosis)~~

- and the gram-negatives:
- Helicobacter pylori, hepaticus, coronari
- Klebsiella (pneumoniae and rhinoscleromatis)
- Salmonella typhimurium
- Serratia (marcescens, corralina, indica, plymuthica, kiluea)
- Neisseria meningitidis
- Escherichia coli

5

Sub B7)

C<sup>10</sup>

[GOODWIN C.S. "Helicobacter Pylori: 10th anniversary of its culture in April 1982". (Gut 1993; 34: 293-4).

C. ERBIN et al. (1977) - Structural studies on the Klebsiella LPS (Carbohydr. Res., 56, 377-81).

15

C

C.B. CASTOR et al. (1971) - Characteristics of a highly purified pyrogenic LPS of Klebsiella pneumoniae (J. of Pharm. Sci. 60, (10), 1578-80).

20

K. FUKUSHI (1964) - Extraction and purification of endotoxin from Enterobacteriaceae: a comparison of selected methods and sources (J. of Bacteriol. 87, (2), 391-400).

C

G. A. LIMJUCO - Studies on the chemical composition of LPS from Neisseria meningitidis group B (J. of Gen. Microbiol. 1978, 104, 187-91).

25

G.A. ADAMS (1967) - Extraction of LPS from gram-negative bacteria with DMSO (Canad. J. Biochem., 45, 422-26).

K.G. JOHNSON (1976) - Improved techniques for the preparation of bacterial LPS (Canad. J. Microbiol. (22),

004574 00500

29-34).

Y.B. KIM et al. (1967) - Biologically active endotoxins from *Salmonella mutans* (J. of Bacteriol., 94, (5), 1320-261)].

5            3 - For the membrane proteins

C            - Helicobacter pylori

C            - Escherichia coli

C            - Serratia marcescens

C            - Streptococcus pyogenes

10 C           - Salmonella typhimurium.

C            Helicobacter pylori, Hepaticus, coronari

GOBERT (B.), LABIGNE (A.), de KORWIN (J.D.),  
CONROY (M.C.), BENE (M.C.), FAURE (G.C.) - Polymerase  
C chain reaction for Helicobacter pylori, (Rev. Esp. Enf  
15 Digest, 1980, 78 (suppl 1), 4.

TOWBIN, H., T. STAEGELIN and J. GORDON, 1979.  
Electrophoretic transfer of proteins from polyacrylamide  
gels to nitrocellulose sheets; procedure and some  
applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.

20            Escherichia coli

S.F. STIRM et al. (1967) - Episome, carried  
C surface antigen K 88 of Escherichia coli (J. of  
Bacteriol., 93, (2), 731-39).

S.J. BETZ et al. (1977) - Chemical and biological  
25 properties of a protein rich fraction of bacterial LPS  
(J. of Immunol., 119 (4), 1475-81).

Serratia marcescens

W. WOBER (1971) - Studies on the protein moiety  
of endotoxin from gram-negative bacteria,

00435747 00000

2

C

5

٤

10

C

15

C

C

20

25

Streptococci, staphylococci and lactobacilli (the surface of gram-positive bacteria is made of teichoic acid, which is a glycerol polymer, linked by phosphodiester bridges).

The following articles describe the methods of production:

M.M. BURGER (1966) - Teichoic acids: antigenic determinants, chain separation and their location in the cell wall (Microbiology 56, 910-17).

K.W. KNOX (1973) - Immunological properties of teichoic acids (Bacteriol. Reviews, 37, 21, 215-57).

G.A. MILLER (1976) - Effects of streptococcal lipoteichoic acid on host response in mice (Infect. and Immun., 1976, 13, (5), 1408-17).

A.J. WICKEN et al. (1975) - Lipoteichoic acids: a new class of bacterial antigens (Science, 187, 1161-67).

#### **Various assays possible**

##### RNA

\* FISKE and SUBBAROW - Assay of phosphorus. HPLC chromatography on an ion-exchange column for qualitative control (J. Biol. Chem. (1926), 66, 375).

##### Proteins

\* LOWRY (J. Biol. Chem. (1951), 193, 265-75).

##### Hexoses

\* T.A. SCOTT - Colorimetric assay using anthrone (Anal. Chem. (1953). 25, 1956-61).

##### Hexosamines

\* L.A. ELSON (Biochem. J (1953), 27, 1824-28).

##### Lipopolysaccharides

\* J. JANDA and E. WORK (Febs Letters, 1971, 16(4), 343-45).

C - The other immunity adjuvant factors, in addition to

the membrane fractions, are

- collagen type III
- sodium chloride

WS  
F<sup>11</sup>

The collagen type ~~VII~~ used is characterized by:

5

a - Amino acid sequences similar to the following sequence (the concentrations are expressed in g/kg):

- aspartic acid	AA	51.5
- hydroxyproline	HP	107.0
- threonine	TH	16.1
- serine	SE	27.8
- glutamic acid	GA	95.9
- proline	PR	124.0
- glycine	GL	149.0
- alanine	AL	87.9
- valine	VA	23.3
- methionine	ME	7.5
- isoleucine	IL	14.4
- leucine	LE	27.8
- tyrosine	TY	6.7
- phenylalanine	PA	14.4
- lysine	LY	28.6
- histidine	HI	5.5
- arginine	AR	73.0

10

15

20

b - The following standard analysis:

25

- colour yellowish white
- apparent density 250 g/l
- moisture 6%
- pH of a 10% solution 6.9
- Engler viscosity at 40°C 2.5

INS  
E1

00154-0000

(17.75% solution)

- fat content 0.9%
- ash content 2.2%
- content of Fe + Cu + Ca 462 mg/kg
- 5 - heavy metals not detectable by arc emission spectrography
- elemental analysis C 46.80%
- H 7.10%
- N 14.96%

10 The composition of the vaccine complex which is  
the subject of the invention, combining ribosomal RNAs or  
RNA fragments, membrane fractions (for example proteo-  
C glycans from Klebsiella pneumoniae) and collagen type  
III, supplemented with sodium chloride and an anti-  
15 inflammatory agent, makes it possible, by administration  
of low doses causing no toxicity, to obtain a high level  
of protection and of cure.

The preferred presentation is the injectable form  
of the composition presented above, but it is possible to  
20 use other presentations and/or other areas or additives  
compatible with a medical use.

#### **Mechanism of action of the vaccine complex**

This therapeutic (vaccine) complex may be assimilated to a specific vaccine (through an "inert system"  
25 which is intended to increase the immunogenicity of a  
recombinant subunit vaccine and of vaccines consisting of  
peptides), and a nonspecific vaccine with the characteristics of a lymphokine, which, by attaching to the  
macrophages, plays an essential role in the immune

5

response to RNA was provided by various inhibitors.

10

15

20

C

[TRIEU-CUOT, P., G. GERBAUD, T. LAMBERT and P. COURVALIN (1985) - In vivo transfer of genetic information between gram-positive and gram-negative bacteria. (EMBO J. 4:3583-3587)].

This mixture, when injected in vivo into mice and guinea pigs, exerts an action on the alveolar macrophages.

This "transient" effect is determined by assaying the acid phosphatase in the direct haemolysis plaques in contact with mouse spleen cells.

The treatment with our therapeutic and vaccine complex is, for its part, followed by a cellular and humoral immunostimulant effect, with a significant specific and nonspecific action on Helicobacter pylori. It is the patient's own body which is stirred into action to "reject the infected cells". A cure is obtained by the action of the PMNs (Polymorphonuclear leukocytes) and of the monocytes simultaneously stirred into action.

[ANDERSEN L.P.; NIELSEN H. Survival and ultrastructural changes of Helicobacter pylori after phagocytosis by human polymorphonuclear leukocytes and monocytes, APMIS; 1993 Jan.: 101(1); 61-72]

[STEIGBIGEL R.T., LAMBERT L. H. & REMINGTON J.S.; Phagocytic and bactericidal properties of normal human monocytes, J. Clin. Invest. 53; 131-142, 1974]

[YAM L.T., Li C.Y. & CROSBY W.H.; Cytochemical identification of monocytes and granulocytes, Am. J. Clin. Pathol. 55; 283-290, 1971].

This therapeutic mechanism therefore makes it possible to produce a natural cloning by virtue of the (nonspecific bacterial ribosomal) RNAs opsonized by the adjuvant developed (combination of membrane proteoglycans, of collagen type III and of sodium chloride).



This cloning induces vaccination against the  
idiotypes of the antibodies, as well as the production of  
antibodies against the site for attachment of the  
bacteria. To reduce or inhibit the inflammatory reaction,  
5 it is necessary to use, during treatments with the  
vaccine complex, corticoids (Betamethasone type, for  
example) in the form of disodium phosphate, at a dose of  
20 to 60 mg, by the I.V. or I.M. route.

This action is also accompanied by production of  
10 endogenous interferon as well as an activation of the NK  
cells.

The aim of our immunomodulatory vaccine complex  
is therefore to induce a local and general immune  
response which has the effect of preventing or at least  
15 of reducing (down to a possible self-defence threshold)  
the proliferation of an infectious agent introduced into  
the body.

- PRUUL H., LEE P.C., GOODWIN C.S. & MACDONALD  
P.J. - Interaction of *Campylobacter pyloridis* with human  
20 immune defence mechanisms, (J. Med. Microbiol. 23; 233-  
238, 1987).

- RATHBONE B.J., WYATT J.I., WORSLEY B.W., SHIRES  
S.E., TREJDOSIEWICZ L.K., HEATLEY R.V. & LOSOWSKY M.S.  
- Systemic and local antibody response to gastric  
C 25 *Campylobacter pyloridis* in non-ulcer dyspepsia, (Gut. 27;  
642-647, 1986).

- STACEY A.R., HAWTIN P.R. & NEWELL D.G. -Local  
C immune responses to *Helicobacter pylori* injections. In:  
C Malgertheimer P. & Ditschuneit H. (Eds.): *Helicobacter*

- C pylori, Gastritis and Peptic Ulcer, (Springer Verlag, Berlin-Heidelberg, 1990, pp. 162-166).

Our therapeutic innovation consists, inter alia, in moderating or eliminating the existence of "suppressive cells" exerting a proinfectious action, in causing an anti-ulcerous reaction by a defensive cellular and/or humoral response; it is the therapeutic response to the problem detected since 1993 by Kist et al.

[KIST M; SPIEGELHALDER C.; MORIKI T.; SCHAEFER

- C 10 H.E. - Interaction of Helicobacter pylori (strain 151) and Campylobacter coli with human peripheral polymorphonuclear granulocytes], and in preventing infectious recidivations.

- BORODY T., ANDREWS P., MANCUSO N., JANKIEWICZ

- C 15 E., BRANDL S. - Helicobacter pylori reinfection 4 years post-eradication; (Lancet 1992, 339-1295).

- BELL G.D., POWELL K.U., BURRIDGE S.M., HARRISON G., RAMEH B., WEIL J. et al. - Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: Implications for treatment of patients with duodenal ulcer disease, (Q.J. Med 1993, 86; 375-382).

- C 20 bacter pylori infection: Implications for treatment of patients with duodenal ulcer disease, (Q.J. Med 1993, 86; 375-382).

In conclusion, our therapeutic complex acts by directed evolution, producing RNA molecules which block the Helicobacter pylori infection and increase the immunodefence.

[SUERBAUM S., C. JOSEPHANS, and A. LABIGNE (1993)

- C - Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin

00125744-082508  
W/B<sup>12</sup>

৯

—

c

—

10

15

## Te

20

- ★

25

By the intravenous route sequences of one week per month may be used, each day of the week of treatment comprising a slow infusion of 500 ml of a solution containing:

- 5           - 0.9% sodium chloride  
            - 40 µg of membrane saccharide fractions

C    (Klebsiella pneumoniae proteoglycans)

- 30 µg of (ribosomal) RNA from:

- C           \* Helicobacter pylori                               7 µg  
C10        \* Diplococcus pneumoniae                           7 µg  
            \* Streptococcus pyogenes (A 12)               7 µg  
            \* Klebsiella pneumoniae                       7 µg  
C           \* Hemophilus influenzae                       2 µg

- 10 µg of collagen type III described above

- 15        - 8 mg of Betamethasone disodium phosphate (that is to say 2 ml of injectable solution).

This treatment by slow I.V. infusion may be replaced by a treatment by subcutaneous injections on patients who can be followed on an ambulatory basis, each  
20 injection containing:

- 40 µg of membrane saccharide fractions

C    (Klebsiella pneumoniae proteoglycans)

- 30 µg of (ribosomal) RNA from:

- C           \* Helicobacter pylori                               7 µg  
C25        \* Diplococcus pneumoniae                           7 µg  
            \* Streptococcus pyogenes (A 12)               7 µg  
            \* Klebsiella pneumoniae                       7 µg  
C           \* Hemophilus influenzae                       2 µg

- 10 µg of collagen type III described above

005280-2425460

- 0.5 ml of sodium chloride at 0.9%

- 4 mg of Betamethasone disodium phosphate (that is to say 1 ml of injectable solution).

This treatment may be continued for several 5 weeks.

By the oral route:

\* using tablets,

2 tablets per day, in a single dose in the morning on an empty stomach, each tablet containing:

10 - 400 µg of membrane saccharide fractions

C (Klebsiella pneumoniae proteoglycans)

- 300 µg of (ribosomal) RNA from:

C \* Helicobacter pylori 70 µg

C \* Diplococcus pneumoniae 70 µg

15C \* Streptococcus pyogenes (A 12) 70 µg

C \* Klebsiella pneumoniae 70 µg

C \* Hemophilus influenzae 20 µg

- 100 µg of collagen type III described above

- 2 mg of Betamethasone disodium phosphate.

20 This treatment can be provided at the rate of 2 tablets per day for one month, followed by booster periods of two tablets per day, one week per month for 3 months.

By the transdermal route

25 Adhesive transdermal therapeutic sytem composed of a reservoir and a permeable membrane providing continuous passage of the active ingredients across the skin and into the bloodstream at a constant rate.

The device should be stuck to a healthy skin

00520-11-20

surface which is dry and not very hairy (side wall of the abdomen or of the thorax for example).

It comprises:

- adhesive polymer
- 5       - carrier for the adhesive: polyethylene
- silicone polyester protective filter

Its content is the content of one tablet, and its dosage is identical to the oral route (at the rate of one "patch" for 2 daily tablets).

10       The following non-limiting examples are given to illustrate the concrete results for our therapeutic vaccine complex.

Example 1

Mr. Robert G., 64 years old, was hospitalized  
15       following epigastralgia, pyrosis and abdominal pain associated with a transit disorder with alternating diarrhoea - constipation. Digestive endoscopy showed a gastrooesophageal reflux pathology by the opening of the cardia, causing an oesophagitis and a peptic ulcer of the  
20       lower oesophagus.

Biopsies were performed, as well as a rapid urease test. The latter, as well as anatomopathology and  
C       culture, confirmed the presence of Helicobacter pylori.

Conventional treatment (antisecretory and two  
25       antibiotics) was prescribed. The tritherapy did not lead to a clinical cure.

Six weeks after the end of the treatment, verification of eradication by the <sup>13</sup>C-labelled urea breath test led to conclusion on the proliferation of bacteria

00125747 00000000

because of its positive nature.

The treatment with the vaccine complex which is the subject of the invention was then carried out in the form of subcutaneous injections.

5           A month later, clinical cure was observed and the carbon-13-labelled urea breath test was negative.

Six months later, another verification by the  $^{13}\text{C}$ -labelled urea breath test and a verification endoscopy showed an established cure.

10           For one year, the cure has been definitive.

Example 2

15           Mr. Serge Y., 48 years old, had a type B antral gastritis. Treatment with immunomodulatory complex (the only previous treatments were gastric dressings) in IV form. Clinical cure was obtained fifteen days after the therapeutic sequence. The verifications ( $^{13}\text{C}$ -labelled urea breath test) have been negative for one year.

Example 3

20           Mr. Pierre K. had a duodenal ulcer confirmed by endoscopy (+biopsy, urease test, ELISA tests).

Treatment by the oral route was then introduced. Three weeks later, clinical cure was obtained.

Six weeks later, verification by the  $^{13}\text{C}$ -labelled urea breath test confirmed the eradication.

25           Six months later, no recidivation was recorded, and the Elisa test showed a nonsignificant (< 50%) antibody level.

Example 4

Mrs. Sarah L. had a duodenal ulcer associated

The presence of gastric cancer was detected among her brothers and sisters. A full check-up was carried out to show the positive nature of all the tests by an invasive method: culture, histology, amplification of the viral genome (PCR), urea test.

10           Given the high familial risk, an endoscopy with  
biopsy was performed from the third month: PCR, cytology,  
culture, CLO test, were negative.

At the sixth month, a breath test ( $^{13}\text{C}$ ) confirmed clinical cure.